U.S. Markets close in 6 hrs 25 mins

Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100

Newsfile Corp.

Oakville, Ontario--(Newsfile Corp. - November 19, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) products and in the development of innovative cannabidiol medicines for heart disease, is pleased to announce the formation of the Clinical Steering Committee ("CSC") for a Phase 2 international trial in acute myocarditis using the Company's CardiolRx™100 cannabidiol formulation.

The CSC, which comprises key opinion leaders in acute myocarditis from North America and Europe, recently met during the American Heart Association's Scientific Sessions in Philadelphia held November 16th to 18th. The role of the CSC is to advise on the trial design, provide overall supervision of the trial, and ensure that it is being conducted in accordance with the principles of Good Clinical Practice. The CSC has oversight of the protocol, any protocol amendments, and provides advice to the investigators on all aspects of the trial.

Acute myocarditis is characterized by inflammation of the heart muscle (myocardium). The most common cause is viral infection of the heart tissue which is initially responsible for the inflammation. In a significant number of cases, perhaps due to an autoimmune process, the inflammation persists with ongoing myocardial damage and depressed heart function. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is the most common cause of sudden cardiac death in people less than 35 years old. In addition, some patients proceed to develop chronic dilated cardiomyopathy which continues to be the leading indication for cardiac transplantation. Symptoms include chest pain, fatigue, shortness of breath, and arrhythmias. Because of the progressive damage to heart cells, heart failure develops (defined as the inability of the heart to pump sufficient blood to meet the needs of the body). The study will use left ventricular ejection fraction (LVEF) as one measure of heart function.

CardiolRx™100 is Cardiol Therapeutics' pure pharmaceutically (cGMP) produced high concentration cannabidiol formulation that is THC free (<10ppm). Based on the large body of experimental evidence of the anti-inflammatory and cardioprotective properties of cannabidiol in models of cardiovascular disease, Cardiol believes there is an opportunity to develop a potential breakthrough therapy for acute myocarditis that would be eligible for designation as an orphan drug. In the United States, an orphan drug designation is granted for pharmaceuticals being developed to treat medical conditions affecting fewer than 200,000 people. These conditions are referred to as orphan diseases. In the U.S. and the European Union, orphan drugs are eligible for accelerated marketing approvals and companies developing orphan drugs typically receive other incentives, including a prolonged period of market exclusivity that can extend over seven years, during which the drug developer has sole rights to market the drug.

"Cardiol has assembled eight highly distinguished thought leaders in cardiology from North America and Europe to oversee and guide our acute myocarditis trial that is being planned at world leading heart institutes, including the Cleveland Clinic, the Mayo Clinic, the Houston Methodist DeBakey Heart and Vascular Center, the University of Ottawa Heart Institute, and Charité University Medicine Berlin," stated David Elsley, President and CEO of Cardiol Therapeutics. "The U.S. orphan drug program was successfully utilized to accelerate the first FDA approval of cannabidiol for the treatment of two pediatric epilepsy orphan diseases. We see a similar opportunity with our international trial in acute myocarditis to fast track the development of our CardiolRx formulation for a serious cardiovascular orphan disease for which there is currently no accepted standard of care."

Members of Cardiol's Acute Myocarditis CSC include:

Dennis M. McNamara, MD (Chair)

Dr. Dennis McNamara is a Professor of Medicine at the University of Pittsburgh. He is also the Director of the Heart Failure/Transplantation Program at the University of Pittsburgh Medical Center. Dr. McNamara received his undergraduate/graduate education at Yale University, New Haven, Connecticut, and Harvard Medical School, Boston, Massachusetts, respectively. He completed his internship, residency, and cardiology fellowship at Massachusetts General Hospital in Boston. McNamara's current research interests include etiology and pathogenesis of dilated cardiomyopathies; inflammatory syndromes of cardiovascular disease; myocardial recovery in recent onset non-ischemic primary cardiomyopathy; etiology and management of peripartum cardiomyopathy; and genetic modulation of outcomes in cardiovascular disease.

Leslie T. Cooper, Jr., MD (Co-Chair)

Dr. Leslie T. Cooper, Jr., is a general cardiologist and the chair of the Mayo Clinic Enterprise Department of Cardiovascular Medicine, as well as chair of the Department of Cardiovascular Medicine at the Mayo Clinic in Florida. Dr. Cooper's clinical interests and research focus on clinical and translational studies of rare and undiagnosed cardiomyopathies, myocarditis, and inflammatory cardiac and vascular diseases, such as giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis, and Takayasu's arteritis. He has published over 130 original peer-reviewed papers, as well as contributing to and editing books on myocarditis. In addition to his clinical and research work, Dr. Cooper is a fellow of the American College of Cardiology, the American Heart Association, the European Society of Cardiology Heart Failure Association, the International Society for Heart and Lung Transplantation, and the Society for Vascular Medicine and Biology. He is also the founder and former president of the Myocarditis Foundation and continues to serve on its Board of Directors.

Arvind Bhimaraj, MD

Dr. Arvind Bhimaraj is a specialist in Heart Failure and Transplantation Cardiology and is Assistant Professor of Cardiology, Institute for Academic Medicine, at Houston Methodist and at Weill Cornell Medical College, NYC. He has been Co-Director of the Heart Failure Research Laboratory at Houston Methodist since 2016. His area of focus is anti-fibrotic mechanisms and how to promote recovery of a damaged heart. Dr. Bhimaraj was a Heart Failure Fellow at the Cleveland Clinic from July 2010 to September 2011. Dr. Bhimaraj also specializes in Interventional Cardiology, is board certified in Cardiovascular Disease, and the author of numerous cardiovascular publications.

Matthias Friedrich, MD

Dr. Matthias Friedrich is Full Professor with the Departments of Medicine and Diagnostic Radiology at the McGill University in Montreal and Chief, Cardiovascular Imaging at the McGill University Health Centre. He is also Professor of Medicine at Heidelberg University in Germany. Dr. Friedrich earned his MD at the Friedrich-Alexander-University Erlangen-Nürnberg, Germany. He completed his training as an internist and cardiologist at the Charité University Medicine Center, Humboldt University in Berlin. Dr. Friedrich founded one of the first large Cardiovascular Magnetic Resonance centres in Germany at the Charité University Hospital in Berlin. After his move to Canada, from 2004 to 2011, he was Director of the Stephenson Cardiovascular MR Centre at the Libin Cardiovascular Institute of Alberta and Professor of Medicine within the Departments of Cardiac Sciences and Radiology at the University of Calgary, Canada. From 2011 to 2015, he directed the Philippa and Marvin Carsley Cardiovascular MR Centre at the Montreal Heart Institute and was Michel and Renata Hornstein Chair in Cardiac Imaging at the Université de Montréal.

Peter Liu, MD

Dr. Peter Liu is the Chief Scientific Officer and Vice President, Research, of the University of Ottawa Heart Institute, and Professor of Medicine and Physiology at the University of Toronto and University of Ottawa. He was the former Scientific Director of the Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research, the major federal funding agency for health research in Canada. Prior to that role, he was the inaugural Director of the Heart & Stroke/Lewar Centre of Excellence in Cardiovascular Research at University of Toronto. Dr. Liu received his MD from the University of Toronto, and postgraduate training at Harvard University. His laboratory investigates the causes and treatments of heart failure, the role of inflammation, and the identification of novel biomarkers and interventions in cardiovascular disease. Dr. Liu has published over 300 peer-reviewed articles in high impact journals and received numerous awards in recognition of his research and scientific accomplishments.

Wai Hong Wilson Tang, MD

Dr. Wai Hong Wilson Tang is the Advanced Heart Failure and Transplant Cardiology specialist at the Cleveland Clinic in Cleveland, Ohio. Dr. Tang is also the Director of the Cleveland Clinic's Center for Clinical Genomics; Research Director, and staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine in the Sydell and Arnold Miller Family Heart & Vascular Institute at the Cleveland Clinic. He attended and graduated from Harvard Medical School in 1996, having over 23 years of diverse experience, especially in Advanced Heart Failure and Transplant Cardiology. Dr. Tang is affiliated with many hospitals including the Cleveland Clinic and cooperates with other doctors and physicians in medical groups including The Cleveland Clinic Foundation.

Barry Trachtenberg, MD

Dr. Barry H. Trachtenberg is a cardiologist specializing in heart failure and cardiac transplantation. He is also the director of the Michael DeBakey Cardiology Associates Cardio-Oncology program, an evolving field devoted to prevention and management of cardiovascular complications of cancer therapies such as chemotherapy and radiation. His clinical experience includes heart failure and heart transplantation, mechanical support pumps, and cardio-oncology. He has contributed to multiple publications related to advanced heart failure, cardiac transplantation, regenerative therapies, and ventricular assist devices. Dr. Trachtenberg is a member of the American Heart Association, the International Society for Heart and Lung Transplantation, the Heart Failure Society of America, and the International CardiOncology Society of North America.

Carsten Tschöpe, MD

Dr. Carsten Tschöpe is Professor of Medicine and Cardiology and Vice Director of the Department of Internal Medicine and Cardiology, Charité University Medicine Berlin. He received his doctorate in medicine in 1993 and has over 140 peer-reviewed publications, including overview and book articles, and 120 international original articles. His research interests include inflammatory cardiomyopathy, diabetic cardiopathy, and ischemic cardiopathy. He also includes diastolic dysfunction, endothelial dysfunction, peptide systems, and experimental and clinical studies in cardiology and stem cells in his research studies. For his outstanding research work, Dr. Tschöpe was awarded the prestigious Arthur Weber Prize by the German Cardiac Society - Cardiovascular Research.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx™, is designed to be one of the safest and most consistent CBD formulations on the market. CardiolRx is pharmaceutically produced, cGMP certified, and is THC free. The Company plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is also pursuing distribution opportunities in Europe and Latin America.

In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit www.cardiolrx.com.

For further information, please contact:

David Elsley, President & CEO

Trevor Burns, Investor Relations

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, that address activities, events or developments that Cardiol Therapeutics Inc. ("Cardiol") believes, expects or anticipates will, may, could or might occur in the future are "forward- looking information". Forward-looking information is frequently identified by the use of words such as "plans", "expects", "projects", "intends", "believes", "anticipates", "forecasts", and other similar words and phrases, including variations (and negative variations) of such words and phrases, or may be identified by statements to the effect that certain actions, events or conditions "may", "could", "should", "would", or "will" be taken, occur or be achieved. Forward-looking information contained herein may include, but is not limited to, statements with respect to: future events; the future performance or the intended business strategy of Cardiol, including, but not limited to, the plan to commercialize CardiolRx100 and the planning of an international clinical study of CardiolRx in acute myocarditis; the potential for Cardiol's licensed drug encapsulation and delivery technologies to enhance the bioavailability of pharmaceuticals; management's expectations regarding estimated future pharmaceutical research and development opportunities, collaborations and prospects; the success and proposed timing of Cardiol's product development activities; the ability of Cardiol to develop its product candidates; Cardiol's plans to research, discover, evaluate and develop additional products; Cardiol's proposed future collaborations to advance Cardiol's lead nanoformulations into clinical development; and the potential for Cardiol's cannabinoid-based products to provide sources of future revenue. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. These risks and uncertainties and other factors include that the success of Cardiol's product candidates will require significant capital resources and years of clinical development efforts; the results of clinical testing and trial activities of Cardiol's products; Cardiol's ability to obtain regulatory approval and market acceptance of its products; Cardiol's ability to raise capital and the availability of future financing; Cardiol's lack of operating history; unforeseeable deficiencies in the development of Cardiol's product candidates; uncertainties relating to the availability and costs of financing needed in the future for Cardiol's research and development initiatives; Cardiol's ability to manage its research, development, growth and operating expenses; the potential failure of clinical trials to demonstrate acceptable levels of safety and efficacy of Cardiol's product candidates; Cardiol's ability to retain key management and other personnel; risks related to fluctuations in medicinal cannabinoid markets in Canada and worldwide; uncertainties regarding Cardiol's ongoing collaborative and manufacturing partnerships; uncertainties regarding results of researching and developing products for human use; Cardiol competes in a highly competitive and evolving industry; Cardiol's ability to obtain and maintain current and future intellectual property protection; and other risks and uncertainties and factors. These risks, uncertainties and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events or results or otherwise. Although Cardiol believes that the expectations reflected in the forward-looking information are reasonable, they do involve certain assumptions, risks, and uncertainties and are not (and should not be considered to be) guarantees of future performance. It is important that each person reviewing this news release understands the significant risks attendant to the operations of Cardiol.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49863

  • Business

    Micron, Western Digital stocks climb after Morgan Stanley turns bullish

    Shares of Micron Technology Inc. (mu) and Western Digital Corp. (wdc) are up about 2% each in premarket trading Thursday after Morgan Stanley analyst Joseph Moore upgraded both stocks to overweight from equal weight. "The higher trough and the elevated valuation environment for semis suggests memory rerating potential even give the moves we have already seen." Micron's stock has added 32% over the past three months, and Western Digital's has gained 19% as the S&P 500 (spx) has risen 11%. Moore's channel checks point to "real conviction" from customers that the memory market will get tighter throughout this calendar year, which is causing them to put more inventory in place.

  • Mark Cuban: Where the ‘frothy’ market goes from here depends on one thing

    Mark Cuban: Where the ‘frothy’ market goes from here depends on one thing

    “Interest rates were a lot different back then,” he continued. Cuban said that, with so much money pouring into index funds, the landscape is completely different from back then. A day earlier, fellow billionaire Paul Tudor Jones, from the sidelines of the World Economic Forum in Davos, said we are currently in the “craziest monetary and fiscal mix in history,” and, at least to him, it's reminiscent of 1999.

  • Young trader’s epic Beyond Meat stock misfire: ‘Biggest mistake of my life’

    Young trader’s epic Beyond Meat stock misfire: ‘Biggest mistake of my life’

    For veteran Wall Street types, $12,000 is a rounding error, but for a guy getting his feet wet in the options pits, losing that much will leave a scar. Unfortunately, that's what happened this week to an anonymous trader whom we'll call “Juice,” if the sob story he shared on Reddit is accurate. “I thought I'd give options a try because I was doing pretty well swing trading and it was probably the biggest mistake of my life,” he wrote in a post.

  • That letter from the IRS could be a fake. Watch out for this tax scam and others in 2020

    That letter from the IRS could be a fake. Watch out for this tax scam and others in 2020

    Fraudsters want your Social Security number and other key personal information in order to file fake tax returns as early as they can in the season to claim inflated tax refunds. Weed at work:New cannabis-based products cause workplace confusion Porsche's revamp : How the SUV boom changed Porsche So, the con artists will be busy long before the April 15 tax deadline. The crooks want to e-file tax returns before you do because they know that the Internal Revenue Service system will reject a tax return when the IRS has already received another return using the same Social Security number.

  • Business

    General Electric Shares Jump Higher After Morgan Stanley Rating, Price Target Boost

    General Electric Co. shares were indicated higher in pre-market trading Thursday after analysts at Morgan Stanley boosted their trading and price target on the stock ahead of its fourth quarter earnings report next week. Morgan Stanley analyst Joshua Pokrzywinski, who reinstated his coverage on GE in September of last year, lifted his rating on the stock by one notch, to overweight, with a $3 improvement to his price target, which now stands at $14 per share. Pokrzywinski cited what he considered to be declining tail risks from GE's power business as well as its long-term pension and healthcare liabilities.

  • Want to Retire in Five Years? What You Must Know

    Want to Retire in Five Years? What You Must Know

    This is as simple as making a list of the items or experiences you expect to spend money on and determining how much they are likely to cost. One way is to use your current budget as the starting point. Then eliminate/lower the expenses that will no longer apply (such as the gasoline you use to commute to and from work) and add/increase the items that will represent new expenses during retirement (such as higher home utility bills or more leisure travel).

  • I’m 38 with $315,000 saved for retirement, but have $30,000 in debt. Should I lower my 401(k) contributions to get rid of that debt?

    I’m 38 with $315,000 saved for retirement, but have $30,000 in debt. Should I lower my 401(k) contributions to get rid of that debt?

    Dear Catey, I currently have about $315,000 in retirement savings and am 38 years old. I have about $30,000 in consumer debt (this is the only debt we carry, no car payment or mortgage) — about $24,000 of which is an unsecured loan that I'm paying about 10% interest on; the rest is on credit cards that are on a 0% promotional period and that I hopefully pay off before the 0% period expires in October 2020. I'm trying to pay down my debt and continue to save aggressively for retirement…I've made minimal improvements over the past couple of years paying down my debt and continue to play the balance transfer game on credit cards to retain 0% interest rates or other low rate options.

  • Here’s how the stock market has performed during past viral outbreaks, as China locks down 3 cities

    Here’s how the stock market has performed during past viral outbreaks, as China locks down 3 cities

    According to Dow Jones Market Data, the S&P 500 posted a gain of 14.59% after the first occurrence of SARS back in 2002-03, based on the end of month performance for the index in April, 2003. About 12 months after that point, the broad-market benchmark was up 20.76% (see attached table): SARS resulted in a total of about 8,100 people being sickened during the 2003 outbreak, with 774 people dying, according to data from WHO and the Centers for Disease Control and Prevention. Separately, the S&P 500 rose 11.66% in the roughly six months following reports of the 2006 Avian flu virus — a fast-moving pathogen also known as H5N1.

  • Elon Musk is about to get even richer: Morning Brief
    Yahoo Finance

    Elon Musk is about to get even richer: Morning Brief

    At Wednesday's closing price, the first tranche of options eligible to be awarded to Musk would be tied to shares worth around $962 million. Musk's strike on these stock awards is $350.02, meaning he'd stand to make just over $371 million if he sold all the options immediately. The market cap milestones start at $100 billion.

  • Bernie Sanders Reacts to Hillary Clinton's Comments Saying 'Nobody Likes Him'
    Meredith Videos

    Bernie Sanders Reacts to Hillary Clinton's Comments Saying 'Nobody Likes Him'

    Hillary Clinton says “nobody likes” her former presidential rival Bernie Sanders, even as the Vermont senator remains entrenched among the front-runners in the Democratic race

  • Beyond Meat Stock Falls On This Red Flag For Fake Meat
    Investor's Business Daily

    Beyond Meat Stock Falls On This Red Flag For Fake Meat

    Beyond Meat stock dropped Wednesday after news of slowing sales for top rival Impossible Foods raised fears of weaker demand for fake meat overall. Carrols Restaurant Group, which is the top U.S. franchisee of Burger King with over 1,000 locations, said Impossible Whopper sales have fallen to 28 per store per day from 32 previously, according to Bloomberg. While sales have stabilized, the Impossible Whopper has been added to the two-for-$6 discount menu temporarily vs. the suggested price of $5.59 per burger.

  • Business

    8 Stocks To Buy With Dividend Yields Of At Least 9%

    Fortunately, there are plenty of stocks out there with generous dividend or distributions yields that analysts see as good investments as well. Here are eight stocks to buy with at least 9% yields, according to Bank of America. TCG is a business development company, a type of closed-end investment company that invests in small and mid-sized businesses.

  • Business

    Co-Diagnostics stock nearly triples after completion of design work for coronavirus screener

    Shares of Co-Diagnostics Inc. (codx) nearly tripled (up 177%) on heavy volume in premarket trading Thursday, after the molecular diagnostics company said it had completed principle design work for a polymerase chain reaction (PCR) screening test for new coronavirus. Trading volume soared to 1.9 million shares, enough to make the stock the most actively traded before the open, and already more than 10-times the full-day average of about 161,000 shares.

  • Boeing's new CEO orders rethink on key jetliner project

    Boeing's new CEO orders rethink on key jetliner project

    LONDON/CHICAGO (Reuters) - Boeing Co's new chief executive has sent the aerospace giant back to the drawing board on proposals for a new mid-market aircraft, effectively shelving in their current form plans worth $15 billion-$20 billion that had been overtaken by the 737 MAX crisis. A decision on whether to launch a New Midsize Airplane (NMA) seating 220-270 passengers, which seemed imminent barely a year ago, had already been postponed as Boeing gave all its attention to the grounding of the smaller 737 MAX after two fatal crashes. A Boeing spokesman said Calhoun had ordered up a new study on what kind of aircraft was needed.

  • Wiping out the nation’s student-loan debt could have unintended financial consequences for borrowers

    Wiping out the nation’s student-loan debt could have unintended financial consequences for borrowers

    Here are some of the ways student-loan forgiveness could affect borrowers' finances: Student-debt cancellation would raise tax bills under existing rules A cancelled loan means people no longer have to pay a lender, but current IRS rules say borrowers — with certain exceptions for scammed students, permanently disabled veterans and public-sector workers — still have to pay the tax authority before they can get out from under a student loan. Take a hypothetical borrower who owes almost $18,000. That's the median student-loan balance for all borrowers, according to the Federal Reserve Bank of New York.

  • Nokia CEO Suri Sees 5G Market Maturity in 2021

    Nokia CEO Suri Sees 5G Market Maturity in 2021

    Nokia Chief Executive Officer Rajeev Suri discusses the impact of the rollout of 5G wireless technology on the company and the telecom industry. He speaks with Bloomberg's Haslinda Amin at the World Economic Forum's annual meeting in Davos, Switzerland on "Bloomberg Markets."

  • JPMorgan: 3 High-Yield Dividend Stocks to Snap Up Now

    JPMorgan: 3 High-Yield Dividend Stocks to Snap Up Now

    It's not that they are necessarily incompatible – rather, it is just that the highest growth stocks tend to achieve their appreciation by plowing profits directly back into the company. The natural place to look is in sectors with high cash flows and essential products. Investment bank JPMorgan released a special report on the North American energy industry, emphasizing just these attributes – the rising production, the high cash flow, and the fundamental strength of the industry to survive a prolonged period of low prices.

  • New FDA documents shed light on agency's rejection of Sarepta drug
    American City Business Journals

    New FDA documents shed light on agency's rejection of Sarepta drug

    Patient deaths, testing concerns and “weak arguments.” Those are just a few of the issues the FDA had with Sarepta Therapeutics's recent drug application, according to new documents released this week. The FDA offered a rare peek at its decision-making process Wednesday, releasing documents related to its initial rejection and later approval of Sarepta's (Nasdaq: SRPT) rare disease drug Vyondys 53. Sarepta CEO Doug Ingram previously declined to release the rejection letter.

  • Boeing's new 777X test aircraft taxis hard before first flight
    American City Business Journals

    Boeing's new 777X test aircraft taxis hard before first flight

    UPDATE: Boeing said Wednesday evening that the 777X first flight has been postponed until Friday because of bad weather. An Everett aviation enthusiast captured Boeing's 777X test aircraft taxiing hard down a Paine Field runway several times Wednesday prior to the widebody jet's first flight. Plane spotter Jennifer Schuld, a full-time nurse by profession and recreational airplane spotter, recorded the 777X taxi tests from a spot adjacent to a runway near the Boeing factory.

  • Is Tesla Stock A Buy Right Now? Here's What Earnings, Charts Show
    Investor's Business Daily

    Is Tesla Stock A Buy Right Now? Here's What Earnings, Charts Show

    Tesla stock has a history of being erratic, with its mercurial Chief Executive Elon Musk frequently drawing attention with bold claims about production and profitability that have been a challenge for analysts to discern. Now, with production of the Tesla Model 3 in full swing, including at its new China plant, and with the company's Model Y and Cybertruck truck in development stages, Musk has defied skeptics once again. Tesla stock has surged to record highs over the past 7 weeks, reaching a market valuation above $100 billion for the first time, on Jan. 22.

  • Business

    Hess and 5 More Energy Stocks That Could Cut Their Dividends, According to an Analyst

    Meyer is particularly concerned about companies that produce a lot of natural gas because the price has been falling and could continue to drop. Meyer identified two stocks— (HES) and (ARX)—that she says have a “a sizable risk of cutting their dividends over the next 1-2 years. Hess (HES) has a dividend payout ratio of 362% of expected 2020 profits, according to Meyer, meaning the company is planning to pay out far more cash to investors than it is earning.

  • Mnuchin to Greta Thunberg — go study economics first

    Mnuchin to Greta Thunberg — go study economics first

    President Donald Trump has taken a few digs at 17-year-old environmental activist Greta Thunberg, and now Treasury Secretary Steven Mnuchin has as well. Speaking at a press conference Thursday with Commerce Sec. Wilbur Ross at the World Economic Forum in Davos, Mnuchin was asked about Thunberg's recommendation to divest from fossil fuels, according to Reuters.

  • Business

    Kimberly-Clark earnings beat expectations, raises 2020 dividend

    Kimberly-Clark Corp. kmb) stock inched up 0.8% in Thursday premarket trading after the consumer products company reported fourth-quarter earnings that beat expectations and raised its 2020 dividend. Kimberly-Clark brands include Kleenex tissues, Huggies diapers, and Cottonelle bathroom products.

  • ‘Taxpayers are leaving millions of dollars off their returns.’ Why Americans repeatedly overlook this lucrative tax credit

    ‘Taxpayers are leaving millions of dollars off their returns.’ Why Americans repeatedly overlook this lucrative tax credit

    Some 44% possibly eligible for the credit — by making less than $40,000 a year — were not aware of it, according to a new survey from the tax preparation company Jackson Hewitt. More than half of the same group either said they did not qualify (20%) or didn't know if they qualified (33%), according to the survey. The results reinforce past research on lagging claim rates for a program that was started 45 years ago.

  • Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’

    Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’

    Jamie Dimon doesn't have much positive to say about negative interest rates in Europe and Japan or public policy in the United States during the past decade. The JPMorgan Chase & Co. (JPM) Chairman and CEO blasted the policy of negative interest rates adopted in Europe and Japan during an interview Wednesday with CNBC, while arguing that economic growth in the U.S. could have been nearly double its actual rate if the government policy had been better. Dimon took aim at fiscal and other economic policies in place at the U.S. federal level.